Biolinq Raises $100M to Revolutionize Painless, Continuous Glucose Monitoring

San Diego-based health tech company Biolinq has secured $100 million in Series C funding, led by Alpha Wave Ventures, to transition from development to commercialization of its next-generation wearable glucose monitoring device. The core innovation lies in its MEMS-fabricated microneedle electrode array, designed to continuously and painlessly measure glucose levels beneath the skin without penetrating sensitive dermal nerve tissues. Unlike traditional CGMs from industry giants like Abbott and Dexcom, Biolinq’s minimally invasive biosensor offers more stable electrochemical readings over time, reducing signal drift. Targeting non-insulin-dependent type 2 diabetes patients, the patch-like sensor provides real-time metabolic feedback via a color indicator, and is designed for future multi-analyte monitoring, including lactate and ketones. The funding supports ongoing U.S. regulatory trials and lays the groundwork for commercial launch, aiming to democratize metabolic health insights through intuitive wearable technology.